is there a lawsuit against tirzepatide class-action has been filed CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients Lilly asks to join lawsuit

Until comprehensive data are available, clinicians and patients should approach retatrutide with appropriate caution and rely on evidence-based alternatives where available

GLP-1 receptor agonist medications like semaglutide and tirzepatide mimic this hormone at therapeutic levels, creating a powerful, sustained effect that your body's natural GLP-1 alone can't achieve

Some people begin to lose a few pounds during this periodoften water weight initially

Dose adjustments of these agents are likely to be necessary under medical supervision

The weight loss effects of tirzepatide are notable, as obesity is a major risk factor for the development of T2DM and cardiovascular diseases